Senior Scientist, Bioinformatics and Data Science, RTI International
Rebecca Boyles has 20+ years of experience in environmental health science research with a focus on data science applications, including data management technologies and data integration. She has particular expertise in designing data-driven research methods and architectures to support research collaborations. She is currently the Co-Principal Investigator of the NHLBI BioData Catalyst Coordinating Center, a Project Director on the NIH Data Commons Facilitation Center, the Co-Director of Infrastructure for the Environmental Influences on Child Health Outcomes (ECHO) Data Analysis Center, a member of the North Carolina Precision Health Collaborative Steering Committee, and co-leads the RTI Women in STEM Employee Resource Group.
While a data scientist at the National Institute of Environmental Health Sciences (NIEHS), Ms. Boyles was instrumental in advancing the strategic plan for knowledge management and data science through the establishment of a new data science program. She initiated efforts to improve access to resources and customized training that support the information needs of NIEHS staff; providing customized, information/knowledge solutions; and creating an infrastructure and culture surrounding data management, interoperability, and sharing. Additionally, she served on the project teams for the NIH Big Data 2 Knowledge Initiative that included the Data Discovery Index and the Community-Based Standards effort. Ms. Boyles is trained as a toxicologist and has previously managed large human health assessments for the US EPA and commercial clients that led to the development of software tools, still used in the field and by US EPA, designed to streamline scientific data extraction, large modeling applications, and risk assessments while providing needed transparency and change management.
Adam Buchanan, MS, MPH, LGC, is assistant professor and genetic counselor in the Geisinger Genomic Medicine Institute. Previously, he was a research associate at Duke Cancer Institute. He is an NIH-funded investigator with research interests in outcomes of genomic screening programs, service delivery models for genetics services, clinical decision support based on family health history, and assessing cancer risk management behaviors. His clinical expertise includes intimate knowledge of recommended risk management for hereditary cancer syndromes. He is co-leading Geisinger’s MyCode genomic screening program for medically actionable genomic results, and is helping to develop a health services research portfolio on patient-participant, family, and system outcomes of this program.
Chief Science Officer, Innovation and Value Initiative, Geisinger National Precision Health
Dr. Deverka is currently the Chief Science Officer at the Innovation Value Initiative, a non-profit organization focused on advancing the science and improving the practice of value assessment in healthcare. Previously, she was the Director of Value Evidence and Outcomes at Geisinger National Precision Health, where she was responsible for assessment of the clinical and economic impact of population exome sequencing for health systems and self-insured employers. Prior to joining Geisinger, she worked closely with clients to develop evidence of the value of healthcare interventions to inform payer, clinician, patient and health system decision-making. Dr. Deverka is a recognized expert in the area of coverage and reimbursement for new genomic-based technologies and has worked collaboratively with stakeholders to recommend standards for a more predictable reimbursement pathway. While working in academia and several non-profit firms, she has participated in numerous NIH-funded studies to evaluate policy barriers to clinical integration of new genomic technologies, and has published extensively on strategies to promote evidence generation and data sharing. Deverka also spent nearly 15 years in the pharmaceutical and pharmacy benefit management industries leading departments of outcomes research and is a thought leader in approaches for demonstrating product value. She has a medical degree from the University of Pittsburgh and is board certified in General Preventive Medicine and Public Health. She also has a master’s degree in bioethics from the University of Pennsylvania and completed a policy fellowship at Duke University’s Institute for Genome Sciences and Policy.
Vice President, Precision and Transformative Medicine, Evidera
Eric Faulkner, MPH, is the Vice President, Precision and Transformative Medicine is and Executive Team member of the Development, Value and Access Consulting unit of Evidera, a PPD company. He brings approximately 25 years of experience in the healthcare industry focusing on value demonstration, product commercialization, and market access/reimbursement. At Evidera, he focuses on health technologies with significant disruptive potential which have complex access issues or requirements such as personalized medicine, diagnostics, orphan drugs, combination products, cell therapy and regenerative medicine, immuno-oncology and vaccines, and e-connectivity technologies.
Eric is a recognized global thought leader in emerging technology market access, with extensive publication and over 100 global panel sessions on these topics. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and serves on the Leadership Committees of the Medical Device and Diagnostics Special Interest Group (former Co-Chair), and Founding Chair of ISPOR’s Personalized Medicine Special Interest Group (now a Leadership Committee member). He also serves on the Leadership Committee for Reimbursement and Business Models for the International Society for Cellular Therapy (ISCT) and Value Demonstration and Market Access & Steering Committee for Health Economics for the Alliance for Regenerative Medicine (ARM) & ARM Foundation
Mr. Faulkner also serves as an adjunct Assistant Professor for the Institute for Pharmacogenomics and Individualized Therapy at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill and as the Executive Director of the Genomics Biotech and Emerging Medical Technology Institute of the National Association of Managed Care Physicians, one of the largest US payer leadership bodies which includes a >100 commercial payer Executive Leadership Council and approximately 40 manufacturer members from all health technology sectors.
Director, Duke Center for Applied Genomics & Precision Medicine
Dr. Ginsburg is the founding director for the Duke Center for Applied Genomics & Precision Medicine and of Duke MEDx. He also founded Genomic Medicine in the Duke Institute for Genome Sciences & Policy (2004-2014) and the Center for Personalized Medicine established in the Duke University Health System (2010-2014). He is Professor of Medicine, Pathology, and Biomedical Engineering.
Dr. Ginsburg has pioneered translational genomics, initiating programs in genome enabled biomarker discovery, longitudinal registries with linked molecular and clinical data, biomarker-informed clinical trials, and the development of novel practice models and implementation research for the integration of genomic tools in health care systems. He has led the development of predictive models for common complex diseases using high dimensional genomic data and collaborates with engineering groups to develop novel point of care sensors. He is an internationally recognized expert in genomics and personalized medicine with over 200 published papers, and funding from NIH, DOD, DARPA, the Gates Foundation, and industry.
He has been a member of the Secretary of Veterans Affairs Advisory Council on Genomic Medicine and the National Advisory Council for Human Genome Research at NIH and is currently a member of the international expert panel for Genome Canada, the Board of External Experts for the NHLBI, the External Scientific Panel for the Pharmacogenomics Research Network, the Advisory Council for the National Center for Advancing Translational Sciences at NIH, and the World Economics Forum’s Global Agenda Council on Personalized and Precision Medicine. He is Vice Chair of the NIH Cures Acceleration Network and co-chairs the Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health. He is the editor of Genomic and Personalized Medicine (2nd edition, Elsevier, 2012).
Research Director, Value-Based Payment Reform-Duke Margolis Center for Health Policy
Marianne Hamilton Lopez, PhD, MPA is Research Director of the Value-Based Payment Reform portfolio at Duke-Margolis. In this role, she manages the Center’s activities aimed at identifying barriers and facilitating implementation of new value-based payment models for pharmaceuticals, including gene therapies, and medical devices. She oversees the Developing a Path to Value-Based Reimbursement for Medical Products Consortium and partners with Duke University faculty, scholars, and external health experts to advance this work.
Prior to joining Duke-Margolis, Dr. Hamilton Lopez was a senior program officer with the National Academy of Medicine’s Leadership Consortium for a Value & Science-Driven Health System and provided strategic direction and oversight of the Consortium’s Science and Technology portfolio and Clinical Effectiveness Research Innovation and the Digital Learning Collaboratives. She was a Senior Manager at AcademyHealth; a Public Health Community Advisor for the United States Cochrane Center; and the Federal Women’s Program Manager and American Indian/Alaska Native Employment Program Manager for the National Institutes of Health.
Director of Data Technology and Innovation, Center for Data Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
Allison Heath is the Director of Data Technology and Innovation responsible for providing technical and collaborative leadership to build platforms for data-driven discovery that span across both research and operational efforts. She provides supervision of the data products and platforms team which performs basic and applied research in data intensive computing, bioinformatics, cloud computing, and related areas. Since joining CHOP in 2017, Allison and her team have been working on solving big data challenges in the unique context of pediatric diseases, including leading the development of the Kids First Data Resource Center (DRC).
Prior to joining CHOP, Allison was the Director of Research at the Center for Data Intensive Science of the University of Chicago. In this position, she led a several large-scale data-intensive projects, including the NCI Genomic Data Commons, the Open Science Data Cloud, and the Bionimbus Protected Data Cloud.
Allison completed BS, MS, and PhD degree programs in Computer Science at Rice University in Houston, TX. She is committed to accelerating discovery and translational research by democratizing data access and analysis.
Chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Research, Levine Cancer Institute, Atrium Health
Edward S. Kim, MD is Chair of Solid Tumor Oncology and Investigational Therapeutics, Medical Director of the Clinical Trials Office, and the Donald S. Kim Distinguished Chair for Cancer Research at the Levine Cancer Institute, Atrium Health in Charlotte, NC.
Dr. Kim was previously at UT MD Anderson Cancer Center in Houston, Texas where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology.
Dr Kim received his Bachelor of Science and medical degrees from the Honors Program in Medical Education (HPME) at Northwestern University, his residency at Baylor College of Medicine, and his fellowship in medical oncology at UT MD Anderson Cancer Center.
Dr Kim specializes in cancer biomarkers and novel targeted agents in the treatment and prevention settings and has expertise in lung, head and neck cancers. He chaired the Department of Defense Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer. He currently oversees the solid tumor faculty and research development at Levine Cancer Institute.
Dr Kim is the author or coauthor of more than 100 published articles, book chapters, reviews in journals such as Lancet, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research Cancer, and Cancer Prevention Research, involving cancer therapeutics and prevention with chemotherapy and novel targeted agents, with particular emphases on lung cancer and head and neck cancer.
Dr. Khoury is the founding director of the CDC’s Office of Public Health Genomics. The Office was formed in 1997 to assess the impact of advances in human genetics and the Human Genome Project on public health and disease prevention. He received his B.S. degree in Biology/Chemistry from the American University of Beirut, Lebanon and his medical degree and Pediatrics training from the same institution. He received a Ph.D. in Human Genetics/Genetic Epidemiology and training in Medical Genetics from Johns Hopkins University. Dr. Khoury is board certified in Medical Genetics. In 1994, he received the Arthur Fleming Award for outstanding government service. In 1998, Dr. Khoury was credentialed for the Senior Biomedical Research Service for outstanding contributions to public health. In 2000, he received the CDC Research Honor Award for outstanding national leadership in genetics and public health. Since 2007, he has served the National Cancer Institute as senior advisor in public health genomics in the Division of Cancer Control and Population Sciences External. Between 2011 and 2015 he led the Epidemiology and Genomics Research Program External in the same Division. Since 2017, he has served the Center for Translation Research and Implementation Science External at the National Heart, Lung, and Blood Institute as a senior advisor in public health genomics.
He has over 500 scientific publications including articles, books and book chapters. In 1993, he published his first book entitled: “Fundamentals of Genetic Epidemiology”. In 2000, he was the lead editor for the book entitled: “Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease”. His most recent book published in 2010 is the second edition of “Human Genome Epidemiology”. Dr. Khoury is a member of many professional societies and serves on the editorial boards of several journals. He is a frequent keynote speaker at many academic institutions, professional organization meetings, as well as state, regional, national and international conferences. He also serves on several scientific, public health, and health policy national and international committees. He is an adjunct professor of Epidemiology at Emory’s School of Public Health and an associate in the Department of Epidemiology at Johns Hopkins University Bloomberg School of Public Health.
Advanced Analytics R&D Senior Manager, JMP Life Sciences Division, SAS
Kelci Miclaus, PhD, is Advanced Analytics R&D Senior Manager for the JMP Life Sciences division at SAS. She manages the development team and release cycles for the JMP Genomics and JMP Clinical software solutions. Additionally, she actively researches and implements new statistical methods for analyzing biological data and clinical trials safety/efficacy data that are incorporated in software releases of JMP Genomics and JMP Clinical respectively. Miclaus earned her PhD in Statistics from North Carolina State University with a research emphasis on biometrics and statistical genetics.
Dr. Jeffrey Shaman is the Chief Science Officer at Coriell Life Sciences where his expertise in genetics, pharmacology, stem cells, and clinical laboratory operations is used to develop and promote genetic and medication risk reporting tools for healthcare professionals and patients.
Dr. Shaman earned his MS from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology, and a PhD from The Johns Hopkins University School of Medicine in Pharmacology & Molecular Sciences, where his research focused on DNA, epigenetics, and nuclear structure and function. Subsequently, he held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before moving to Harvard Medical School, Beth Israel Deaconess Medical Center, and the Bedford Stem Cell Research Foundation, where he bridged the gap between research and medicine thru genetic and clinical medicine initiatives. Dr. Shaman was recruited to Coriell Life Sciences from an international DNA sequencing provider, where he established Translational Genomics activities as a revenue-rich market vertical providing regulatory (FDA) and clinical (CLIA/CAP) services to international pharmaceutical companies, healthcare providers, physicians, and patients. He continues to lecture and publish on topics including pharmacogenomics, bioethics, and clinical care.